Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report issued on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald upped their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA opened at $4.75 on Friday. Vanda Pharmaceuticals has a 52-week low of $3.30 and a 52-week high of $6.75. The firm has a market capitalization of $276.44 million, a price-to-earnings ratio of -59.38 and a beta of 0.77. The stock has a 50 day moving average price of $5.39 and a 200 day moving average price of $5.13.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The firm had revenue of $50.47 million during the quarter. Analysts forecast that Vanda Pharmaceuticals will post -0.49 earnings per share for the current year.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of VNDA. Price T Rowe Associates Inc. MD boosted its holdings in Vanda Pharmaceuticals by 18.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 2,425 shares during the last quarter. Panagora Asset Management Inc. boosted its stake in shares of Vanda Pharmaceuticals by 4.3% in the second quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 2,509 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Vanda Pharmaceuticals by 65.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 4,387 shares in the last quarter. Susquehanna Fundamental Investments LLC raised its position in shares of Vanda Pharmaceuticals by 2.1% in the second quarter. Susquehanna Fundamental Investments LLC now owns 287,677 shares of the biopharmaceutical company’s stock valued at $1,625,000 after buying an additional 5,994 shares during the last quarter. Finally, Meeder Asset Management Inc. acquired a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at about $39,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.